GeNeuro, Switzerland

GeNeuro is a Swiss-based clinical stage company committed to bringing safe and effective solutions for stopping the progression of disability caused by autoimmune diseases, starting with Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS). By leveraging insights into Human Endogenous Retroviruses (HERVs), which account for over 8% of human DNA and may contribute to autoimmune conditions, GeNeuro is advancing temelimab, a monoclonal antibody targeting HERV-W Env, a HERV protein found in the brain of MS patients. Temelimab has shown a coherent impact across all key MRI markers associated with disease progression and has been successfully tested at the Karolinska Institute’s Academic Specialist Center in Stockholm on a cohort of patients experiencing disability progression in the absence of relapses, due to a concomitant treatment with an efficacious anti-inflammatory drug, to confirm its potential against the progression of disability, which is the key unmet need for MS patients. The company is currently running the first biomarker-based Phase 2 clinical trial against neuropsychiatric syndromes affecting Long-COVID patients. GeNeuro has also entered into a partnership with the National Institute of Neurological Disorders and Stroke (NINDS), launching a preclinical development program of a novel antibody targeting HERV-K Env


Hervé Perron

During his PhD Hervé had isolated and characterized a novel retroviral element from Multiple Sclerosis (initially named MSRV), itself defining a novel family of human endogenous elements (HERV-W) that now appears to be implicated in other autoimmune diseases. He is the author of over 100 peer-reviewed publications and patents and is a referee for various scientific journals. After holding several management positions at Biomérieux, Hervé co-founded GeNeuro S.A.  with the motivation to actively involved in the research and development of innovative therapeutics for diseases associated with human endogenous retroviruses. Today, Hervé is the Chief Scientific Officer of GeNeuro S.A. and the general manager of GeNeuro Innovation subsidiary.

Research info

Benjamin Charvet

Benjamin, PhD, is Senior Scientist at GeNeuro Innovation. His initial training was in developmental biology field completed by a post-doctoral in virology. He is in charge of R&D project management for GeNeuro innovation, including the HERVCOV project. He has extensive experience in the field of HERVs, particularly in the relationship between exogenous viruses and HERVs.

Research info

Joanna Brunel

Joanna is Project Manager and Laboratory Manager at GeNeuro Innovation. She has a master’s degree in cellular and molecular biology and is working in the field of immunovirology for 15 years.

Research info

Justine Pierquin

Justine is Research Engineer at GeNeuro Innovation. She has a master’s degree in infectiology and is now focusing of HERV biochemistry and immunovirology of SARS-CoV-2.

Research info

Nelly Queruel

Nelly is Research Engineer at GeNeuro Innovation. She has a master’s degree in health sciences and technology and works on immunobiology and HERV biochemistry.